Pharmacogenomic Testing

All women with breast cancer should undergo genetic testing for BRCA1 and BRCA2 mutations, according to study findings presented at San Antonio Breast Cancer Symposium.

COVID-19 has caused major physical and psychological harm for millions of Americans.

Use of a combinatorial pharmacogenomic test appeared associated with improved outcomes among patients with major depressive disorder, according to data presented at the American Society of Clinical Psychopharmacology Annual Meeting.

A combinatorial pharmacogenomic test significantly improved outcomes among patients with major depressive disorder who had at least one prior medication failure, according to results of a randomized controlled trial published in The Journal of Clinical Psychiatry.